%0 Journal Article
%T Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment
%A Health Quality Ontario
%J Archive of "Ontario Health Technology Assessment Series".
%D 2017
%X Prostate cancer is very common and many localized tumours are non-aggressive. Determining which cancers are aggressive is important for choosing the most appropriate treatment (e.g., surgery, radiation, active surveillance). Current clinical risk stratification is reliable in forecasting the prognosis of groups of men with similar clinical and pathologic characteristics, but there is residual uncertainty at the individual level. The Prolaris cell cycle progression (CCP) test, a genomic test that estimates how fast tumour cells are proliferating, could potentially be used to improve the accuracy of individual risk assessment. This health technology assessment sought to determine the clinical utility, economic impact, and patients' perceptions of the value of the CCP test in low- and intermediate-risk localized prostate cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451271/